Uterine Leiomyosarcoma Clinical Trial
Official title:
A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
This is a randomized phase II study of letrozole (Femara) administered 2.5 mg orally daily to patients with newly diagnosed clinical stage I and II LMS. Using an adaptive randomization, patients will be assigned to either the treatment arm (letrozole group) or observation. The primary outcome for this trial is the time to progression. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00390234 -
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT00245102 -
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
|
Phase 2 | |
| Completed |
NCT00378911 -
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
|
Phase 2 | |
| Withdrawn |
NCT02378142 -
Pazopanib for Treating Uterine Leiomyosarcoma
|
Phase 2 | |
| Active, not recruiting |
NCT06244251 -
Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids
|
N/A | |
| Recruiting |
NCT04727242 -
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
|
Phase 2 | |
| Completed |
NCT00659360 -
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT00614835 -
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
|
N/A |